About | Board

Neil Cameron

Neil Cameron – NED

Neil was a Worldwide Consulting Partner at Arthur Andersen. Post Andersen he undertook a variety of entrepreneurial roles with companies including St John Restaurant, Cutting Edge Music and Waterfordchedi AG. Neil is also a founder investor in Caffe Nero. Neil has a degree in Economics and Accounting from the University of Bristol and is a Chartered Accountant. His Parkwalk directorships include Symetrica, Undo and Mediagamma. Neil also is responsible for Parkwalk’s investments in Quantum Computing.

Adrien Desjardins

Professor Adrien Desjardins – Chief Technical Officer

Adrien has a PhD from Harvard and the Massachusetts Institute of Technology (MIT). in Biomedical Engineering and Biophysics with a specific focus on cardiovascular devices, fibre optic sensing, and optical coherence tomography. After his PhD, he led technical developments in an internal venture at Philips Research (Netherlands) to develop devices with integrated optical sensors and brought this technology from benchtop prototypes to in vivo human studies. In addition to his responsibilities at Echopoint Medical, he is a Full Professor at UCL where he leads the interventional devices group with a vision to develop novel methods for performing physiological measurements and imaging with minimally invasive devices. He has over 52 patent applications and granted patents.

Malcolm Finlay

Dr Malcolm Finlay – Chief Medical Officer

Dr Malcolm Finlay is a Consultant Electrophysiologist and Honorary Senior Lecturer at Barts Heart Centre & UCL, London, specialising in minimally invasive treatments for heart disease. In addition to Echopoint, he has invented several medical technologies, including Epicardio Ltd. (4D heart simulation) and STAR Mapping (Rhythm AI Ltd) to aid treatment of atrial fibrillation. Dr. Finlay qualified from Oxford University in 2001, and gained his PhD in Cardiac Electrophysiology in 2014 from UCL, where he held a Wellcome Trust Research Training Fellowship. His work in technological innovation has been recognised by his appointment to the European Heart Rhythm Association Innovations Committee, he is a faculty member for several national and international academic conferences including Heart Rhythm Congress and the European Heart Rhythm Association. Outside of cardiology, his interests include aviation (holding a private pilot’s license), filmmaking (check out “the last trip” from straight8.net), music and sports.

David Grimm

David Grimm – Observer

David manages the UCL Technology Fund, which is investing in commercialisation of life and physical sciences innovations from one of the most important academic institutions in the United Kingdom. He previously worked for 4 years at Spark Impact, a subsidiary of Spark Ventures, investing across medical technology, telehealth and consumer healthcare. He started his career at Detica before moving to China to work in a FMCG start-up. David holds a Masters’ degree in Natural Science (Mathematics and Chemistry).

 Antony Odell

Antony Odell – Executive Chairman

Antony has extensive experience of taking early stage start-ups to full commercial activity and has a career spanning both major multinationals (Johnson & Johnson, Fresenius and Howmedica (Stryker)) as well as a number of spin outs from the NHS (Tayflow Technologies) and universities (Tissue Regenix Group PLC). Most recently at Tissue Regenix he took the company from a two-person spin- out to an AIM-listed company with operations in the UK, Germany and the US. Whilst CEO the company was listed on AIM and completed its first acquisition in the US of CellRight in August 2017. Current assignments include Director of NorthInvest (not for profit Angel network), Director of Tandem Nano Ltd and Executive Chair of EML. Antony owns two miniature dachshunds (Lottie & Lupin) and is a keen if inept gardener. He bakes great sourdough and enjoys cooking Italian and Middle Eastern food.

Dr Weng Sie Wong - NED

Dr Weng Sie Wong – NED

Weng brings extensive experience of all aspects of university technology transfer activities from strategic IP management, marketing and licence negotiations to spin-out formation. Prior to joining UCLB, Weng was a Senior Technology Transfer Manager at Oxford University’s TTO, Oxford University Innovation, working on a diverse range of both life and physical science projects over a 10-year period. Weng holds an MBA from Edinburgh University and a PhD in pharmacology from University College London.